Literature DB >> 16284917

Some considerations on the design of population pharmacokinetic studies.

Stephen Duffull1, Tim Waterhouse, John Eccleston.   

Abstract

The goal of this manuscript is to introduce a framework for consideration of designs for population pharmacokinetic orpharmacokinetic-pharmacodynamic studies. A standard one compartment pharmacokinetic model with first-order input and elimination is considered. A series of theoretical designs are considered that explore the influence of optimizing the allocation of sampling times, allocating patients to elementary designs, consideration of sparse sampling and unbalanced designs and also the influence of single vs. multiple dose designs. It was found that what appears to be relatively sparse sampling (less blood samples per patient than the number of fixed effects parameters to estimate) can also be highly informative. Overall, it is evident that exploring the population design space can yield many parsimonious designs that are efficient for parameter estimation and that may not otherwise have been considered without the aid of optimal design theory.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16284917     DOI: 10.1007/s10928-005-0034-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  12 in total

1.  Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs.

Authors:  S Retout; S Duffull; F Mentré
Journal:  Comput Methods Programs Biomed       Date:  2001-05       Impact factor: 5.428

2.  Optimal design of a population pharmacodynamic experiment for ivabradine.

Authors:  S B Duffull; F Mentré; L Aarons
Journal:  Pharm Res       Date:  2001-01       Impact factor: 4.200

3.  Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics.

Authors:  Sylvie Retout; France Mentré
Journal:  J Biopharm Stat       Date:  2003-05       Impact factor: 1.051

4.  Optimization of individual and population designs using Splus.

Authors:  Sylvie Retout; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  Experimental design and efficient parameter estimation in population pharmacokinetics.

Authors:  M K al-Banna; A W Kelman; B Whiting
Journal:  J Pharmacokinet Biopharm       Date:  1990-08

6.  Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients.

Authors:  Timothy H Waterhouse; Stefanie Redmann; Stephen B Duffull; John A Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

7.  Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.

Authors:  D Z D'Argenio
Journal:  Math Biosci       Date:  1990-04       Impact factor: 2.144

8.  Comparison of some practical sampling strategies for population pharmacokinetic studies.

Authors:  E N Jonsson; J R Wade; M O Karlsson
Journal:  J Pharmacokinet Biopharm       Date:  1996-04

9.  Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.

Authors:  M Tod; J M Rocchisani
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

10.  Prospective evaluation of a D-optimal designed population pharmacokinetic study.

Authors:  Bruce Green; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-04       Impact factor: 2.745

View more
  24 in total

1.  Population pharmacokinetics of lamotrigine in Indian epileptic patients.

Authors:  Surulivelrajan Mallaysamy; Martin G Johnson; Padma G M Rao; Thiyagu Rajakannan; Lokesh Bathala; Karthik Arumugam; Johan G C van Hasselt; Devarakonda Ramakrishna
Journal:  Eur J Clin Pharmacol       Date:  2012-06-02       Impact factor: 2.953

2.  Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.

Authors:  J G Coen van Hasselt; Bruce Green; Glynn A Morrish
Journal:  Pharm Res       Date:  2012-01-13       Impact factor: 4.200

3.  Methods and software tools for design evaluation in population pharmacokinetics-pharmacodynamics studies.

Authors:  Joakim Nyberg; Caroline Bazzoli; Kay Ogungbenro; Alexander Aliev; Sergei Leonov; Stephen Duffull; Andrew C Hooker; France Mentré
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

4.  A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients.

Authors:  Stefanie Hennig; Timothy H Waterhouse; Scott C Bell; Megan France; Claire E Wainwright; Hugh Miller; Bruce G Charles; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2006-10-30       Impact factor: 4.335

5.  Simultaneous versus sequential optimal design for pharmacokinetic-pharmacodynamic models with FO and FOCE considerations.

Authors:  J M McGree; J A Eccleston; S B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-02-18       Impact factor: 2.745

Review 6.  Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Authors:  Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  Informative study designs to identify true parameter-covariate relationships.

Authors:  Phey Yen Han; Carl M J Kirkpatrick; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-03-27       Impact factor: 2.745

8.  Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.

Authors:  Vijay K Siripuram; Daniel F B Wright; Murray L Barclay; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-06-13       Impact factor: 2.745

9.  An alternative method for population pharmacokinetic data analysis under noncompliance.

Authors:  Pankaj Gupta; Matthew M Hutmacher; Bill Frame; Raymond Miller
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-02-26       Impact factor: 2.745

10.  Optimisation of sampling windows design for population pharmacokinetic experiments.

Authors:  Kayode Ogungbenro; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-09       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.